McKesson Corporation (MCK)
McKesson (MCK) Rises Higher Than Market: Key Facts
McKesson (MCK) reachead $699.73 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
McKesson (MCK) Increases Yet Falls Behind Market: What Investors Need to Know
In the latest trading session, McKesson (MCK) closed at $695.17, marking a +1.86% move from the previous day.
McKesson (MCK) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, McKesson (MCK) closed at $694.70, indicating a +0.27% shift from the previous trading day.
3 Safe Dividend Stocks as Investors Seek to Reset Diversification
Over the last three years, diversification has fallen out of fashion. When investors can make 20% or higher returns in technology stocks and even more from the Magnificent 7, the idea of investing in low-growth dividend stocks loses some appeal.
Why the Market Dipped But McKesson (MCK) Gained Today
McKesson (MCK) closed the most recent trading day at $679.33, moving +1.13% from the previous trading session.
MCK Stock Gains as PRISM Acquisition Adds High-Growth Business
McKesson acquires 80% ownership in PRISM Vision Holdings, diversifying its business into the high-growth area of ophthalmology. The deal is to be accretive this year.
McKesson Shares Up Over 2% After Key Signal
MCK IS UP OVER 14 POINTS AFTER THE TRADEPULSE ALERT
McKesson Gets Drugs to Patients. Buy the Stock for Healthy Returns.
An aging U.S. population is increasing the demand for medication, and this company delivers.
McKesson (MCK) Laps the Stock Market: Here's Why
In the most recent trading session, McKesson (MCK) closed at $672.99, indicating a +0.74% shift from the previous trading day.
Wall Street Bulls Look Optimistic About McKesson (MCK): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
McKesson: Immune To Weak Economy And Tariffs; Top Idea In 2025
I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability, making it a reliable investment amid economic uncertainties. The company's GLP-1 and oncology franchises are key growth drivers, with GLP-1 revenue growing 45% year-over-year and oncology patient visits increasing steadily.
